Study guide

13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections

Key Takeaways Explain This Topic AI

While asthma is more common in boys during childhood, post-pubertal and adult females exhibit substantially higher asthma prevalence, hospitalization rates, and severity, frequently driven by hormonal fluctuations (perimenstrual or catamenial asthma).

The GINA reports establish Track 1—low-dose Inhaled Corticosteroid (ICS) combined with formoterol as Single Maintenance and Reliever Therapy (SMART/MART)—as the preferred therapeutic paradigm across Steps 1 through 5, eliminating reliance on short-acting beta-2 agonist (SABA) monotherapy.

Asthma in pregnancy adheres to the "Rule of Thirds" (one-third improve, one-third worsen, one-third remain stable), with peak vulnerability to exacerbation occurring between weeks 24 and 36 of gestation.

Uncontrolled maternal asthma presents a far greater risk of fetal hypoxemia, intrauterine growth restriction, preeclampsia, and preterm delivery than any standard asthma medication; inhaled corticosteroids (budesonide preferred, or continuing effective prior ICS) and albuterol rescue are safe throughout pregnancy and lactation.

In primary care respiratory infections, acute bronchitis is overwhelmingly viral (>90%) and antibiotics should be strictly withheld in favor of symptomatic care, while Community-Acquired Pneumonia (CAP) is stratified by CURB-65 criteria and treated empirically with amoxicillin or doxycycline (or beta-lactam plus macrolide in pregnancy, avoiding fluoroquinolones and tetracyclines).

Last updated: October 2026

Sex Differences in Asthma Epidemiology & Perimenstrual Asthma

Asthma is a chronic inflammatory airway disorder characterized by bronchial hyperresponsiveness, mucosal edema, and variable airflow obstruction. A notable epidemiologic shift occurs across the lifespan: in children under age 12, asthma prevalence and hospitalizations are twice as high in boys compared to girls, reflecting smaller airway caliber relative to lung volume. Following puberty, this sex ratio reverses. Adult women exhibit significantly higher asthma prevalence, more frequent severe exacerbations, increased emergency department visits, and more than double the hospitalization rates of men.

Female sex hormones profoundly modulate airway biology:

Estrogen & Progesterone Influences: 17-beta-estradiol promotes Th2 eosinophilic airway inflammation and upregulates nitric oxide synthase, while progesterone influences airway smooth muscle tone and beta-2 adrenergic receptor density.

Perimenstrual Asthma (PMA / Catamenial Asthma): Between 30% and 40% of asthmatic women experience cyclical worsening of symptoms and peak expiratory flow (PEF) in the premenstrual and early menstrual window (days -4 to +2 of menses). PMA is triggered by the rapid drop in circulating estradiol and progesterone, producing a surge in pro-inflammatory cysteinyl leukotrienes and heightened bronchial hyperreactivity. Management strategies include adding a leukotriene receptor antagonist (LTRA; montelukast 10 mg PO daily), premenstrual step-up of inhaled corticosteroids, or hormonal suppression of cyclical drops with continuous combined oral contraceptives.

Stepwise Asthma Pharmacotherapy: The GINA & NHLBI Guidelines

The Global Initiative for Asthma (GINA) no longer recommends short-acting beta-2 agonist (SABA) monotherapy (as-needed albuterol alone), and the 2020 NHLBI focused update endorses ICS-formoterol single maintenance and reliever therapy (SMART) for moderate persistent asthma (steps 3–4). SABA monotherapy relieves bronchospasm without treating underlying inflammation, leading to beta-receptor downregulation, tolerance, rebound hyperresponsiveness, and increased exacerbation risk.

GINA designates Track 1 (ICS-Formoterol as Single Maintenance and Reliever Therapy, SMART/MART) as the preferred strategy across all severity steps:

Step GINA Track 1 (Preferred: SMART / MART) GINA Track 2 (Alternative Strategy)

Step 1 & 2 As-needed low-dose ICS-formoterol (e.g., budesonide-formoterol 80/4.5 or 160/4.5 mcg, 1 puff PRN for relief) Daily low-dose ICS maintenance PLUS as-needed SABA (or take low-dose ICS whenever SABA is inhaled)

Step 3 Low-dose ICS-formoterol maintenance (1 puff daily or BID) PLUS as-needed low-dose ICS-formoterol reliever Daily low-dose ICS-LABA maintenance PLUS as-needed SABA

Step 4 Medium-dose ICS-formoterol maintenance (2 puffs BID) PLUS as-needed low-dose ICS-formoterol reliever Daily medium-to-high dose ICS-LABA maintenance PLUS as-needed SABA

Step 5 High-dose ICS-formoterol maintenance + add-on LAMA (tiotropium); phenotyping for biologic therapy Daily high-dose ICS-LABA + add-on LAMA; phenotyping for biologic therapy

Formoterol is uniquely suited for SMART because it provides rapid bronchodilation (onset 1–3 minutes, comparable to albuterol) alongside a 12-hour duration of action. Taking ICS-formoterol for symptom relief delivers anti-inflammatory corticosteroid at the earliest sign of airway worsening. In Step 5, phenotypic evaluation directs add-on biologics: anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab), anti-IL-4R-alpha (dupilumab), and anti-TSLP (tezepelumab).

Asthma Management in Pregnancy & Lactation

Asthma affects 8% to 10% of pregnant women. Its clinical course classically follows the "Rule of Thirds" :

One-third of women experience symptom improvement (mediated by increased free cortisol and progesterone).

One-third remain unchanged.

One-third experience symptom worsening, with peak vulnerability occurring between weeks 24 and 36 of gestation (exacerbations during active labor are rare, <10%).

Important

Clinical Principle: Uncontrolled Asthma vs Medication Safety in Pregnancy: Uncontrolled maternal asthma presents a far greater risk to maternal and fetal well-being than any standard asthma medication. Maternal hypoxemia impairs uteroplacental perfusion, causing fetal hypoxia, intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, preterm delivery, and low birth weight.

Inhaled Corticosteroids (ICS): The foundation of persistent asthma care. Budesonide has the most extensive human pregnancy safety data; however, if a patient is well-controlled on another ICS (e.g., fluticasone, mometasone) prior to pregnancy, she should continue her established medication to avoid loss of disease control.

Rescue Bronchodilator: Inhaled albuterol is the preferred first-line SABA in pregnancy.

Systemic Steroids: For moderate-to-severe exacerbations, oral prednisone (40–60 mg/day for 5 days) or IV methylprednisolone must not be withheld; maternal stabilization is essential to prevent fetal asphyxia.

Lactation: Budesonide, fluticasone, and albuterol transfer into breast milk in negligible amounts and are safe during breastfeeding.

Acute Exacerbation Triage & Fetal Oxygenation Targets

Progesterone stimulates the medullary respiratory center, increasing minute ventilation by 30% to 50% and producing a physiologic chronic respiratory alkalosis (normal pregnancy PaCO2: 28–32 mmHg; pH: 7.40–7.45; HCO3: 18–22 mEq/L). Consequently, a "normal" PaCO2 of 35 to 40 mmHg during an asthma exacerbation indicates respiratory muscle exhaustion and impending respiratory arrest.

Maternal pulse oximetry must be maintained at SpO2 ≥95% (or PaO2 >70 mmHg) at all times to guarantee adequate transplacental oxygen delivery to the fetus. Treatment includes high-flow oxygen, repetitive nebulized albuterol (2.5 mg) plus ipratropium bromide (0.5 mg), systemic corticosteroids, continuous fetal monitoring if viable (≥24 weeks), and serial peak flow measurements.

  • Upper & Lower Respiratory Infections in Primary Care
  • Acute Bronchitis

Acute bronchitis is a self-limiting inflammation of the large airways presenting with cough (with or without sputum), wheezing, and chest discomfort lasting 10 to 21 days (median 18 days).

Etiology: Over 90% of cases are viral (influenza, parainfluenza, RSV, coronavirus, rhinovirus). Bacterial pathogens (Bordetella pertussis, Mycoplasma pneumoniae) account for <10%.

Antimicrobial Stewardship: Antibiotics are strictly not indicated , as randomized trials demonstrate no reduction in cough duration alongside significant adverse effects and resistance risks.

Symptomatic Relief: Patient education regarding the typical 2- to 3-week course, hydration, guaifenesin (expectorant), dextromethorphan (antitussive), and honey (patients >1 year). Inhaled albuterol is reserved strictly for auscultated wheezing.

Community-Acquired Pneumonia (CAP)

Pneumonia presents with fever, chills, productive cough, dyspnea, and focal lung crackles or consolidation confirmed on chest radiography (with abdominal shielding in pregnancy).

CURB-65 Criteria: Confusion (1 pt), Urea/BUN >20 mg/dL (1 pt), Respiratory rate ≥30/min (1 pt), Blood pressure <90/60 mmHg (1 pt), Age ≥65 (1 pt). Score 0–1: outpatient care; Score 2: consider hospital admission; Score ≥3: inpatient admission.

Outpatient Antibiotic Regimens:

Healthy adults: Amoxicillin 1 g PO TID OR Doxycycline 100 mg PO BID (macrolide monotherapy only if local resistance <25%).

Adults with comorbidities: Amoxicillin-clavulanate (875/125 mg PO BID) PLUS a macrolide (Azithromycin) or Doxycycline; OR respiratory fluoroquinolone monotherapy (Levofloxacin 750 mg daily).

Gestational Safety Contraindications:

Fluoroquinolones (levofloxacin, ciprofloxacin): Contraindicated in pregnancy and lactation due to fetal cartilage damage and arthropathy.

Tetracyclines (doxycycline): Contraindicated in the 2nd and 3rd trimesters due to permanent fetal tooth discoloration and bone growth inhibition.

Pregnancy First-Line: Amoxicillin-clavulanate (875/125 mg BID) PLUS oral Azithromycin (500 mg day 1, then 250 mg daily) .